We have shown previously that tri-iodothyronine (T 3 )-induced sex hormone-binding globulin (SHBG) secretion by the human hepatoblastoma cell line, HepG2, can be modulated by retinoids. We have now used this model to study a range of other compounds that are known to influence T 3 responsiveness in various cell systems. HepG2 cells were incubated for 4 days in serum-free medium containing T 3 , together with insulin, dexamethasone, phorbol myristate (PMA), sodium butyrate or estradiol. T 3 (10 nmol/l) alone induced a concentration of SHBG secreted by HepG2 cells that was 187Ϯ20% (meanϮS.D., n=9) of control. Insulin (100 nmol/l) reduced basal SHBG secretion from 24.7Ϯ5.2 nmol/l to 16.1Ϯ1.7 nmol/l (P<0.01). This effect was dose responsive, half-maximal at 3.4Ϯ3.0 nmol/l (Ϸ600 mU/l) and maximal with 100 nmol/l insulin. Co-incubating 0-10 nmol/l T 3 with 100 nmol/l insulin resulted in a downward shift in the dose-response curve without a change in the half-maximal response to T 3 . Conversely, 0-100 nmol/l insulin reduced SHBG production induced by 10 nmol/l T 3 . In contrast, while dexamethasone alone was without effect on SHBG secretion, 100 nmol/l dexamethasone induced a shift to the left in half-maximal T 3 stimulation from 0.37 nmol/l to 0.10 nmol/l. The effect of PMA on SHBG secretion was reminiscent of the previously observed retinoid effect. PMA 100 nmol/l abolished maximal T 3 stimulation. This effect was dose responsive, with a threshold at 1 nmol/l PMA. Sodium butyrate, up to 1 mmol/l was without effect; with greater concentrations, SHBG secretion was reduced. T 3 responsiveness was virtually abolished by 3 mmol/l sodium butyrate; higher concentrations were cytotoxic and secretion was reduced to less than 20% of basal. Lack of an effect of estradiol on SHBG secretion by HepG2 cells was confirmed. These studies suggest that T 3 -induced SHBG secretion by HepG2 cells is independently influenced by insulin, potentiated by dexamethasone, and modulated by PMA. Detailed molecular analysis of this model will increase our understanding of the mechanism of action of T 3 , specifically in human liver cells. [415][416][417][418][419][420] 
Introduction
Sex hormone-binding globulin (SHBG) is a glycoprotein synthesised and secreted by the liver (1, 2) . The primary function of SHBG is probably the binding of gonadal steroids in the circulation, which influences the bioavailability and metabolic clearance of these ligands (3) . SHBG is also postulated to have other roles distinct from its binding and transport function. For example, it binds to a surface receptor localised on a number of steroid-responsive tissues and may have a critical role in regulating steroid-induced cell growth (4) . This model is unusual in that only SHBG in the unliganded state can bind to its receptor; steroid must be added after the initial binding reaction in order to stimulate a cellular response. SHBG is also of diagnostic utility. It responds to thyroid hormone (tri-iodothyronine, T 3 ) and has been postulated to be a marker for thyroid hormone resistance (5) . Patients expressing mutations in the T 3 receptor fail to respond normally to exogenously administered T 3 and do not show the expected increase in serum SHBG concentrations.
Taken together, these observations suggest that there is a need for detailed understanding of the factors controlling SHBG secretion, both in vivo and in vitro. Serum SHBG is regulated predominantly by sex steroids and has a pivotal role in amplifying the bioavailable concentration of circulating estrogen in humans (6) . In addition, SHBG concentrations are influenced by a range of other hormones including T 3 and insulin (7) (8) (9) (10) (11) . There is a clear correlation between SHBG concentrations and thyroid status: thyrotoxic patients have increased serum SHBG concentrations that return to normal in response to anti-thyroid therapy (12) . In contrast, SHBG is negatively correlated with fasting insulin concentrations (13) , and hyperinsulinemic insulin resistance and obesity are associated with a reduction in circulating SHBG (14) . It has been suggested that low SHBG concentrations contribute to increased androgenisation in conditions such as the polycystic ovary syndrome (6) .
In previous studies from our laboratory, we have developed an in vitro test system to study SHBG production. T 3 in physiological concentrations doubles the secretion of SHBG by the human hepatoma cell line, HepG2 (8, 15) . This response is preceded by a similar change in the concentration of SHBG mRNA synthesised by the cells (8) . A sequence homologous to a thyroid response element can be identified in the promoter region of the SHBG gene and this gene has been proposed as a potential model to investigate the mechanism of action of T 3 in a human cell line (8, 9) . Interestingly, the secretion of SHBG by HepG2 cells under T 3 stimulation can be modulated by retinoids in a manner which suggests that a nuclear cofactor(s) is necessary for full responsiveness of SHBG gene transcription (15) .
Other studies using HepG2 cells have demonstrated an effect of insulin on SHBG secretion in vitro (7, 10, 11) . Insulin reduced secretion to between 45 and 75% of control after 2-7 days in culture; SHBG mRNA was also reduced in the presence of insulin (10) .
While the SHBG responses to T 3 or insulin in vitro closely parallel those seen in vivo, the interaction between these counter-regulatory factors at the level of protein secretion has not been studied. Furthermore, factors that are known to modify T 3 responsiveness in other cell systems have not been examined in HepG2 cells. This is particularly the case for glucocorticoids, phorbol esters and sodium butyrate, all of which can modulate T 3 -mediated responses in other in vitro models. In the present study, we have used HepG2 cells to investigate the interrelationship between T 3 and insulin, glucocorticoids, phorbol esters and sodium butyrate in order to better our understanding of the factors influencing SHBG secretion and to enhance our understanding of the mechanism of action of T 3 in a human cell line.
Materials and methods
All experiments were performed using HepG2 cells as described elsewhere (8, 15, 16 (8) .
Free T 3 fraction was measured by equilibrium dialysis (17) . Briefly, 1 ml cell supernatant was dialysed overnight at 37 ЊC against 20 ml Tris buffer containing physiological ion concentrations and about 100 000 c.p.m. [ 125 I]T 3 (3000 mCi/mg; New England Nuclear, Boston, MA). The dialysate was corrected for free iodide contamination before the free fraction was calculated.
Where necessary, statistical differences were confirmed using the Student's t-test. A P value of 0.05 or less was regarded as significant.
Results

T 3 and insulin
SHBG secreted by HepG2 cells doubled in response to T 3 in a manner identical to that which we and others have previously observed (Figs. 1-4, left panels). With 10 nmol/l T 3 , the SHBG concentration in cell supernatants was to 187 Ϯ 20% of control (n=9). In contrast, insulin produced a dose-responsive reduction in SHBG secretion, with a maximal response at 100 nmol/l and half-maximal effect at 3.4Ϯ3.0 nmol/l ( conversely, when the insulin response was determined in the presence of a fixed concentration of T 3 ( Fig. 1 , right panel), the half-maximal effects of each hormone were preserved. In the presence of 10 nmol/l T 3 and 100 nmol/l insulin, the SHBG response was 100.7Ϯ11.8%.
T 3 and phorbol esters
We next examined the effect of the phorbol ester, PMA, on the T 3 responsiveness of HepG2 cells. PMA activates protein kinase C which, in turn, activates transcription via the AP-1 protein complex of c-jun and c-fos. There is evidence to suggest that this protein complex can inhibit induction of T 3 responsive genes in artificial reporter systems (18) . PMA alone was without effect on SHBG secretion (Fig. 2, right panel) , but at a concentration of 100 nmol/l, it caused a 50% reduction in T 3 -stimulated SHBG secretion (Fig. 2, left panel) . This effect was dose responsive, with a threshold at a concentration between 0.1 and 1 nmol/l (Fig. 2, right panel) .
T 3 and glucocorticoids
Synergism between T 3 and glucocorticoids is well recognised in rat liver (19) and pituitary cell models (20) . Such interactions at the genetic level are not ubiquitous (21) , but analogous experiments have not been performed in human cells. Accordingly, we also examined the responses in our cell system for evidence of an interaction with glucocorticoids. Dexamethasone up to 100 nmol/l was without effect on SHBG secretion by HepG2 cells (Fig. 3, right panel) . Interestingly, dexamethasone 100 nmol/l promoted a shift in the T 3 dose-response curve by approximately one-half an order of magnitude (Fig. 3, left panel) . There was no change in thyronine-binding globulin secretion (data not shown) and the absence of any change in the free T 3 fraction in cell supernatants (Table 1) suggests that the concentration of other T 3 -binding proteins secreted by these cells also did not change.
T 3 and sodium butyrate
Finally, we examined the effects of an agent that is well recognised as a modulator of T 3 activity because it induces a change in intracellular concentrations of T 3 receptor number. Sodium butyrate modifies histone acetylation and has been shown to influence T 3 responsiveness in rat pituitary cell (22) and glial cell (23) models. In GH3 cells, sodium butyrate virtually abolishes T 3 -mediated gene expression, probably via down-regulation of the thyroid hormone receptor b2 mRNA (24) . In terms of SHBG secretion by HepG2 cells, EUROPEAN sodium butyrate was without effect up to 1 mmol/l (Fig.  4 , right panel), but at greater concentrations it induced a diminution in both control and T 3 -stimulated SHBG secretion (Fig. 4, right panel) . The decrease in protein secretion was accompanied by a loss of cell contact with the incubation wells, suggesting that sodium butyrate was toxic to these cells. In experiments in which a single subthreshold concentration of sodium butyrate was used (Fig. 4, left panel) , the response to T 3 was unaffected.
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Discussion
In this study, we confirmed that T 3 induces a doubling in the concentration of cell-secreted SHBG and we showed that insulin reduces SHBG secretion in a doseresponsive manner, but that dexamethasone and PMA, an activator of protein kinase C, were without effect on this parameter. In contrast, both the glucocorticoid and PMA were able to modulate T 3 -induced SHBG secretion, but sodium butyrate at concentrations up to 1 mmol/l was without effect. Higher concentrations of sodium butyrate were cytotoxic to HepG2 cells, in agreement with earlier studies that showed inhibition of protein secretion and cell growth by sodium butyrate in concentrations greater than 1-2 mmol/l (25) . The cytotoxicity of this agent suggests that HepG2 cells are more sensitive to sodium butyrate than are rat pituitary cells, thus precluding the use of the liver cell line from studies of receptor regulation by this short-chain fatty acid. In addition, we confirmed the inability of HepG2 cells to respond to estradiol (data not shown).
Insulin reduces SHBG secretion with a half-maximal effect at 3.4 nmol/l (Ϸ600 mU/l); the response is maximal at 100 nmol/l. These data are in good agreement with those of Crave et al. (10) , who found an effective half-maximal dose of insulin of 12.8 nmol/l for SHBG secretion and 4.3 nmol/l for SHBG mRNA production. In contrast to that study, we did not observe a decrease in total protein in the presence of insulin. In our cells, total secreted protein remained unchanged or may have increased slightly (less than 20%) over the period of exposure (data not shown). Of particular interest is the relationship between insulin and T 3 in the control of SHBG secretion. Our results suggest that the influence of these two effectors is independent. We found that the T 3 stimulation of SHBG secretion was preserved in the presence of a saturating concentration of insulin, even though basal concentrations were reduced, while the insulin response was also preserved in the presence of a saturating dose of T 3 . SHBG concentrations were normalised in the presence of 10 nmol/l T 3 together with 100 nmol/l insulin. T 3 -induced changes in SHBG mRNA precede and correlate with changes in secreted protein (8) . The effects of insulin on SHBG mRNA also mirror the protein response (10). Our current data suggest that T 3 and insulin independently affect SHBG mRNA to produce the concentration of secreted protein observed in our experiments. Northern blotting and RNA run-on Table 1 Free T 3 fraction determined in supernatants of HepG2 cells exposed to serum-free DMEM for 4 days in the presence of the additives, T 3 and dexamethasone. Each value (mean Ϯ S.D.) was determined in triplicate in three separate experiments. The absolute free T 3 fraction in the controls varied from 0.275 to 0.622. experiments will be required to determine whether these responses reflect a change in transcription, or stabilisation of the relevant mRNA species. The response to PMA is reminiscent of our earlier experiments involving retinoic acid. In the absence of other stimulating factors, PMA had no effect on basal SHBG secretion. However in the presence of T 3 , PMA induced a dose-dependent decrease in the concentration of SHBG produced by HepG2 cells. This effect involved a change in the maximal response, rather than a shift in the dose-response curve, and suggests that PMA influences a co-factor(s) involved in T 3 induction. We previously observed a virtually identical response in similar studies using retinoids (15) . In that study, both all-trans and 9-cis retinoic acid were able to reduce a specifically up-regulated T 3 response. Modulation of any one of a range of newly identified co-activators or co-repressors (26) may produce the results seen with PMA and retinoids, but identification of these factors was beyond the scope of this study. Even so, our results suggest that PMA and retinoids share a common pathway in their ability to influence SHBG secretion.
Perhaps the most interesting finding presented here is the synergistic relationship between T 3 and glucocorticoids in the control of SHBG secretion. Dexamethasone alone had no effect on this response, but in concert with T 3 produced a clear shift to the left in the T 3 doseresponse curve. This effect is broadly similar to the synergism observed between T 3 and glucocorticoids in the synthesis of growth hormone by cultured rat pituitary cells (20) . Responses to dexamethasone have been observed in HepG2 cells (27) but, to our knowledge, the mechanism of these responses has not been characterised. HepG2 cells express glucocorticoid receptors (28) and it is possible that they interact with thyroid hormone receptors on the SHBG gene. Clearly, a complete understanding of this process will require detailed molecular investigation. In clinical terms, apart from the gonadal steroids, only thyroid status (12), insulin and age (29) are considered significant predictors of SHBG concentrations in humans; the role of glucocorticoids and their relationship to T 3 in the control of SHBG secretion has not been investigated. Two recent studies suggest glucocorticoids may influence circulating SHBG concentrations. In women with polycystic ovary syndrome, SHBG concentrations are lower than normal and associated with low nocturnal cortisol concentrations (30) , and in children SHBG has been shown to increase after an infusion of adrenocorticotropic hormone (29) . It is important to note that in neither report was thyroid status considered, and further clinical studies are thus required to confirm that our findings in vitro reflect human responses in vivo.
In conclusion, we have shown that SHBG secretion in the face of hormonal stimulation is variable, depending on the combination of factors to which the cells are exposed. These studies confirm the use of HepG2 cells as an appropriate human cell model in which to study the mechanism of responsiveness to T 3 .
